Mechanisms of resistance to PARP inhibitors - an evolving challenge in oncology
© The Author(s) 2019..
Poly-adenosine diphosphate ribose polymerase inhibitors (PARPi) lead to synthetic lethality when used in cancers harbouring a BRCA mutation or homologous recombination deficiency. There are now four PARPi approved by the Food and Drug Administration for therapeutic use is ovarian and breast cancer. In addition to this, there is data supporting its use in pancreatic adenocarcinoma and prostate cancer. However, development of resistance to PARPi limits the duration of response. Key mechanisms found to date include: (1) restoration of homologous recombination; (2) changes in PARP1; (3) suppression of non-homologous end joining; (4) replication fork protection; and (5) drug concentration. Gaining a better understanding of resistance mechanisms may guide combination therapies to overcome the resistance and improve the efficacy of PARPi. The purpose of this review is to describe the resistance mechanisms to PARPi and discuss their early detection.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:2 |
|---|---|
| Enthalten in: |
Cancer drug resistance (Alhambra, Calif.) - 2(2019), 3 vom: 13., Seite 608-617 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mweempwa, Angela [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
BRCA reversion |
|---|
| Anmerkungen: |
Date Revised 19.05.2022 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.20517/cdr.2019.50 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM341053856 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM341053856 | ||
| 003 | DE-627 | ||
| 005 | 20231226010903.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.20517/cdr.2019.50 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1136.xml |
| 035 | |a (DE-627)NLM341053856 | ||
| 035 | |a (NLM)35582591 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mweempwa, Angela |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Mechanisms of resistance to PARP inhibitors - an evolving challenge in oncology |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 19.05.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © The Author(s) 2019. | ||
| 520 | |a Poly-adenosine diphosphate ribose polymerase inhibitors (PARPi) lead to synthetic lethality when used in cancers harbouring a BRCA mutation or homologous recombination deficiency. There are now four PARPi approved by the Food and Drug Administration for therapeutic use is ovarian and breast cancer. In addition to this, there is data supporting its use in pancreatic adenocarcinoma and prostate cancer. However, development of resistance to PARPi limits the duration of response. Key mechanisms found to date include: (1) restoration of homologous recombination; (2) changes in PARP1; (3) suppression of non-homologous end joining; (4) replication fork protection; and (5) drug concentration. Gaining a better understanding of resistance mechanisms may guide combination therapies to overcome the resistance and improve the efficacy of PARPi. The purpose of this review is to describe the resistance mechanisms to PARPi and discuss their early detection | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a BRCA reversion | |
| 650 | 4 | |a Poly-adenosine diphosphate ribose polymerase inhibition | |
| 650 | 4 | |a homologous recombination | |
| 650 | 4 | |a ovarian cancer | |
| 650 | 4 | |a resistance mechanisms | |
| 700 | 1 | |a Wilson, Michelle K |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer drug resistance (Alhambra, Calif.) |d 2018 |g 2(2019), 3 vom: 13., Seite 608-617 |w (DE-627)NLM292424043 |x 2578-532X |7 nnns |
| 773 | 1 | 8 | |g volume:2 |g year:2019 |g number:3 |g day:13 |g pages:608-617 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.20517/cdr.2019.50 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 2 |j 2019 |e 3 |b 13 |h 608-617 | ||